Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

NCT03706326 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Guangdong Pharmaceutical University as lead sponsor.

NCT NCT03706326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
Lead sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 28, 2018
Completion date
September 28, 2021
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal cancer